Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 8/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26639011 | 0.85 | CA12 (0.41) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL26638882 | 0.72 | KDM4A (0.48) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL26639107 | 0.71 | KDM4E (0.44) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL1414029 | 0.70 | HDAC3 (0.56) | KDM4EGRNSORT1CA12PTPN1 | |
| SCHEMBL26659258 | 0.69 | KDM4E (0.49) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL26104250 | 0.69 | GRN (0.56) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL6835603 | 0.69 | CA12 (0.46) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL26638982 | 0.68 | KDM4A (0.50) | KDM4EGRNSORT1CA12CA1 | |
| SCHEMBL2792109 | 0.67 | PHGDH (0.61) | CA12CA1CA2CA9PTPN1 | |
| SCHEMBL70171 | 0.67 | KDM4E (0.58) | KDM4EGRNSORT1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| EP-4522604-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230365551-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220225-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220225-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365551-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | NHERF1, ACE, METAP1 | KDM4E 4022/4885GRN 3340/4885SORT1 1965/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | KDM4E 3725/4885GRN 3676/4885SORT1 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.